Immunogenicity of vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian model. | ||||
Egyptian Journal of Chemistry | ||||
Articles in Press, Accepted Manuscript, Available Online from 28 April 2024 | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejchem.2024.276701.9459 | ||||
View on SCiNiTO | ||||
Authors | ||||
Mohamed Eid Abo sherif1; Noura Mahrous Abo shama2; Sara M Hussein3; Mohamed Aly El-Desouky 4; Demiana Helmy Hanna 5; Mohamed Ahmed Ali 6 | ||||
1Egyptian Army | ||||
2Eva Pharmaceutical | ||||
3Center of Scientific Excellence for Virus Research,National Research Centre | ||||
4Biochemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt | ||||
5Department of Biochemistry,Faculty of Science,Cairo University | ||||
6El Bohouth St | ||||
Abstract | ||||
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) represents a major threat to human health worldwide. No licensed MERS-CoV vaccines or therapeutics were developed. So, the aim of the current study is the generation and immunological evaluation of DNA vaccine candidate against MERS-CoV. The spike gene was selected to generate the DNA vaccine, which encodes the spike protein of coronaviruses that plays a pivotal role in viral entry into host cells and serves as a primary target for host immune responses. Moreover, the antibody responses post-immunization with spike-DNA fragment and inactivated coronaviruses vaccines was explored, using a microneutralization assay with severe acute respiratory syndrome (SARS-CoV-2), and the log2 antibody titers at different time points (0, 2, 4, 6, and 8 weeks) post-vaccination was measured. The inactivated MERS-CoV and pCDNA3.1-S-MERS-CoV vaccines maintained steady log2 antibody titers, showing no specific response to SARS-CoV-2 in the control group (PBS). Microneutralization against MERS-CoV showed no significant antibody titers for Inactivated SARS-CoV-2, suggesting no cross-reactivity. Sustained antibody titers for Inactivated MERS-CoV indicate vaccine-induced stability. This study sheds light on antibody responses induced by these vaccines against MERS-CoV. These insights are crucial for optimizing vaccine strategies, particularly in the context of the evolving MERS-CoV pandemic. | ||||
Keywords | ||||
Vaccine; spike; MERS-CoV; SARS-CoV-2; antibodies | ||||
Statistics Article View: 148 |
||||